Anti-Rheumatic Rx

      ❓️Is early intensive therapy with combination csDMARDs or TNFi superior to standard step care for the treatment of m

      Nelly ZIADE 🍀 Nellziade

      4 months 2 weeks ago
      ❓️Is early intensive therapy with combination csDMARDs or TNFi superior to standard step care for the treatment of moderate to severe #psoriatic_arthritis? 🅰️ Yes 🔅Check out the SPEED RCT presented by @DrLauraCoates at #EULAR2025 OP0089 @RheumNow #Strategy https://t.co/24e7wUV2FB
      Can RA be intercepted?

      In the ALTO follow-up of the APIPPRA RCT (Cope et al), 1 year of abatacept delayed RA onset by u

      Jiha Lee JihaRheum

      4 months 2 weeks ago
      Can RA be intercepted? In the ALTO follow-up of the APIPPRA RCT (Cope et al), 1 year of abatacept delayed RA onset by up to 3 years in ACPA+/RF+ individuals. Effect strongest in those with mature autoantibody profiles. Abstract#OP0004 @RheumNow #EULAR2025 https://t.co/N7YwtYod8w
      Repurposing drugs to #osteoarthritis

      No jewel in the rough!

      Most drugs - MTX, colchicine, TNFi, IL1i, etc are NEGATIV

      Janet Pope Janetbirdope

      4 months 2 weeks ago
      Repurposing drugs to #osteoarthritis No jewel in the rough! Most drugs - MTX, colchicine, TNFi, IL1i, etc are NEGATIVE or yield mixed results from diff #RCTs Not sure this is the way forward for #OA drug discovery 💡 #EULAR2025 @RheumNow @eular_org Abst#POS565 https://t.co/A6SdXtOo7v
      IL-17 inhibition for PMR?In the secukinumab ph2 in GCA (TitAIN), patients with PMR did really well, seemingly outperfo

      David Liew drdavidliew

      4 months 2 weeks ago

      IL-17 inhibition for PMR? In the secukinumab ph2 in GCA (TitAIN), patients with PMR did really well, seemingly outperforming steroid taper in the placebo arm. Real promise, will be great to see how the ph3 in PMR (REPLENISH) goes OP0062 #EULAR2025 @RheumNow https://t.co/cisA0GiUx1

      If you successfully taper off DMARDs in RA patients in remission, do you risk bringing new joints in the mix?

      Leiden po

      David Liew drdavidliew

      4 months 2 weeks ago
      If you successfully taper off DMARDs in RA patients in remission, do you risk bringing new joints in the mix? Leiden post-hoc trial: these patients don’t do worse than those who never get off drug. Drug-free remission tricky but new joints not a worry. #EULAR2025 @RheumNow https://t.co/QDxNRPN9f1
      Access inequity across Europe is real.

      New #RheumaFacts data show major gaps in RMD care:
      🔹 Full tsDMARD access in j

      Jiha Lee JihaRheum

      4 months 2 weeks ago
      Access inequity across Europe is real. New #RheumaFacts data show major gaps in RMD care: 🔹 Full tsDMARD access in just 4% of countries 🔹 Self-referral possible in 57% 🔹 Rheum physio reimbursed in 63% 🔹 Psych care? Only 30%. Abstract#OP0025 @RheumNow #EULAR2025
      MONITOR-PsA (n=218):
      •36.5% had >1 csDMARD
      •Of those, 49.2% tried combination (combo) csDMARDs
      •63.6% of combo

      Antoni Chan MD (Prof) synovialjoints

      4 months 2 weeks ago
      MONITOR-PsA (n=218): •36.5% had >1 csDMARD •Of those, 49.2% tried combination (combo) csDMARDs •63.6% of combo csDMARD users in MDA at 48wks •61.1% stopped due to side effects—not inefficacy Real-world support for csDMARD combos where biologics delayed. Abstract#OP0093 https://t.co/3Anme39VXk
      Early PsA? Treat fast, treat hard.

      The STAMP RCT showed that early secukinumab + MTX led to faster ACR50 and PASI90 res

      Jiha Lee JihaRheum

      4 months 2 weeks ago
      Early PsA? Treat fast, treat hard. The STAMP RCT showed that early secukinumab + MTX led to faster ACR50 and PASI90 responses vs standard care in a T2T strategy. By 12 months, outcomes were similar, but early SEC needed fewer escalations. Abstract#OP0092 @RheumNow #EULAR2025 https://t.co/cAZTc9eN16
      #OP0066 Danish registry study finds no increased risk of cancer recurrence with bDMARDs vs csDMARDs in RA patients with

      Jiha Lee JihaRheum

      4 months 2 weeks ago
      #OP0066 Danish registry study finds no increased risk of cancer recurrence with bDMARDs vs csDMARDs in RA patients with prior solid tumor in remission. IPTW-adjusted HR for any bDMARD: 0.92 (95% CI 0.38–2.21). 📉 TNFi, ,RTX also not associated with recurrence @RheumNow #EULAR2025
      Can lowering serum urate also lower CV risk? In >116k patients w/ #gout, achieving SU <360 µmol/L in 12m ↓ 5yr

      Mrinalini Dey DrMiniDey

      4 months 2 weeks ago
      Can lowering serum urate also lower CV risk? In >116k patients w/ #gout, achieving SU <360 µmol/L in 12m ↓ 5yr MACE risk (HR 0.89, pooled Δsurvival +1.4%). Greater effect in >65s. Gout management = CV prevention? @RheumNow #EULAR2025 #OP0005 https://t.co/NRAerUBemN
      What happens in pre-RA when you stop #abatacept after 1 yr Rx

      At 6 yrs approx 60% on #Placebo
      V
      50% who initially got

      Janet Pope Janetbirdope

      4 months 2 weeks ago
      What happens in pre-RA when you stop #abatacept after 1 yr Rx At 6 yrs approx 60% on #Placebo V 50% who initially got #ABA Prolonged damped effect of development of #RA NNT for 1 yr is ~10 with a range as low as 6 #EULAR2025 @RheumNow @eular_org Abst#OP0004 https://t.co/1VOEaZ00Ia
      #EULAR2025 Abstr#POS0677 I will be at Poster Area today (1530). Single centre (N=23): Rituximab vs Cyclophosphamide for

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 months 2 weeks ago
      #EULAR2025 Abstr#POS0677 I will be at Poster Area today (1530). Single centre (N=23): Rituximab vs Cyclophosphamide for #Sjogren-Neuropathy. No superiority but clinical response was more complete & longer retention numerically favouring RTX. Support trial of BCDT in SjD @RheumNow https://t.co/87e6yFMRkk

      Catch up on Conference Podcasts

      ×